Trial reportNeurogastroenterology and motility2016
Effects of hemin on heme oxygenase-1, gastric emptying, and symptoms in diabetic gastroparesis.
Trial report in Neurogastroenterology and motility, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 38 citations in OpenAlex.
- GI Dysfunctions in Diabetic Gastroenteropathy, Their Relationships With Symptoms, and Effects of a GLP-1 Antagonist.The Journal of clinical endocrinology and metabolism · 2019Trial
- Electroacupuncture at ST-36 Protects Interstitial Cells of Cajal via Sustaining Heme Oxygenase-1 Positive M2 Macrophages in the Stomach of Diabetic Mice.Oxidative medicine and cellular longevity · 2018Trial
- Utility of aNeurogastroenterology and motility · 2025Article
- New insights into muscularis macrophages in the gut: from their origin to therapeutic targeting.Immunologic research · 2023Review
- Adeno-associated virus-9 reverses delayed gastric emptying of solids in diabetic mice.Neurogastroenterology and motility · 2023Article
- Ten controversies in gastroparesis and a look to the future.Neurogastroenterology and motility · 2023Review
- Gastroparesis.Gastroenterology · 2022Review
- Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders.Frontiers in pharmacology · 2022Review
- New Developments in Prokinetic Therapy for Gastric Motility Disorders.Frontiers in pharmacology · 2021Review
- Heme Oxygenase-1 in Gastrointestinal Tract Health and Disease.Antioxidants (Basel, Switzerland) · 2020Review
- Targeting Heme Oxygenase-1 in the Arterial Response to Injury and Disease.Antioxidants (Basel, Switzerland) · 2020Review
- Relationship between symptoms during a gastric emptying study and intestinal chemosensitivity with daily symptoms.Neurogastroenterology and motility · 2019Article
- Diabetic Gastroparesis.Endocrine reviews · 2019Review
- Muscularis macrophages: Key players in intestinal homeostasis and disease.Cellular immunology · 2018Review
- Diabetic gastroparesis: current challenges and future prospects.Clinical and experimental gastroenterology · 2018Review
- Glass half empty? Lessons learned about gastroparesis.F1000Research · 2018Review
- Diabetes and the Stomach.Current treatment options in gastroenterology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundTherapeutic options for management of diabetic gastroparesis are limited. Failure to maintain upregulation of heme oxygenase (HO1) leads to loss of interstitial cells of Cajal and delayed gastric emptying (GE) in non-obese diabetic mice. Our hypothesis was that hemin upregulation of HO1 would restore normal GE in humans with gastroparesis.
aimsTo compare effects of hemin and placebo infusions on HO1 activity and protein, GE, autonomic function, and gastrointestinal symptoms in diabetic gastroparesis.
methodsIn a single-center, double-blind, placebo-controlled, randomized clinical trial, we compared intravenous hemin, prepared in albumin, or albumin alone (placebo) in 20 patients, aged 41 ± 5 (SEM) years with diabetic gastroparesis. After infusions on days 1, 3, and 7, weekly infusions were administered for 7 additional weeks. Assessments included blood tests for HO1 protein and enzyme activity levels, GE with KEY
resultsNine of 11 patients randomized to hemin completed all study procedures. Compared to placebo, hemin increased HO1 protein on days 3 (p = 0.0002) and 7 (p = 0.008) and HO1 activity on day 3 (p = 0.0003) but not after. Gastric emptying, autonomic functions, and symptoms did not differ significantly in the hemin group relative to placebo. CONCLUSIONS & INFERENCES: Hemin failed to sustain increased HO1 levels beyond a week and did not improve GE or symptoms in diabetic gastroparesis. Further studies are necessary to ascertain whether more frequent hemin infusions or other drugs would have a more sustained effect on HO1 and improve GE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.